{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:45:30Z","timestamp":1786545930633,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1038\/ajg.2010.139","type":"journal-article","created":{"date-parts":[[2010,4,6]],"date-time":"2010-04-06T23:39:25Z","timestamp":1270597165000},"page":"2009-2016","source":"Crossref","is-referenced-by-count":22,"title":["A Population-Based Study of Health-Care Resource Use Among Infliximab Users"],"prefix":"10.14309","volume":"105","author":[{"given":"Zoann","family":"Nugent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210210","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":", ACCENT I Study Group. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial.","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"R2-17-20210210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial.","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"R3-17-20210210","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohns disease: results of the CLASSIC II trial.","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"R4-17-20210210","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohns disease.","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"R5-17-20210210","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohns disease: results from a single-centre cohort.","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"R6-17-20210210","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2036.2008.03919.x","article-title":"Efficacy and complications of adalimumab treatment for medically-refractory Crohns disease: analysis of nationwide experience in Scotland (2004-2008).","volume":"29","author":"Ho","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R7-17-20210210","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2036.2008.03878.x","article-title":"Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients.","volume":"29","author":"Swaminath","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-17-20210210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohns disease: the Mayo clinic experience in 500 patients.","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"R9-17-20210210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1572-0241.2003.04010.x","article-title":"Remission in patients with Crohns disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.","volume":"99","author":"Lichtenstein","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R10-17-20210210","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohns disease.","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"R11-17-20210210","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohns disease.","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"key":"R12-17-20210210","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohns disease: results from the CHARM study.","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"key":"R13-17-20210210","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00005650-199303000-00002","article-title":"Registries and administrative data: organization and accuracy.","volume":"31","author":"Roos","year":"1993","journal-title":"Med Care"},{"key":"R14-17-20210210","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/oxfordjournals.aje.a009735","article-title":"Epidemiology of Crohns disease and ulcerative colitis in a central Canadian province: a population-based study.","volume":"149","author":"Bernstein","year":"1999","journal-title":"Am J Epidemiol"},{"key":"R15-17-20210210","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1111\/j.1572-0241.2001.05255.x","article-title":"Use of pharmaceuticals by IBD patients: a population-based study.","volume":"96","author":"Metge","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R16-17-20210210","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1111\/j.1572-0241.2003.08718.x","article-title":"Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?","volume":"98","author":"Bernstein","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R17-17-20210210","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/ibd.20483","article-title":"Patterns of infliximab use among Crohns disease patients in a community setting.","volume":"14","author":"Pressman","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"R18-17-20210210","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1365-2036.2008.03732.x","article-title":"Comparative effectiveness of azathioprine in Crohns disease and ulcerative colitis: prospective, long term, follow up study of 394 patients.","volume":"28","author":"Gisbert","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-17-20210210","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00004836-200208000-00007","article-title":"Infliximab decreases resource use among patients with Crohns disease.","volume":"35","author":"Rubinstein","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"R20-17-20210210","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/MCG.0b013e3181986917","article-title":"Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohns disease.","volume":"43","author":"Taxonera","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"R21-17-20210210","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1365-2036.2007.03507.x","article-title":"Resource use in patients with Crohns disease treated with infliximab.","volume":"26","author":"Saro","year":"2007","journal-title":"Aliment Pharmacol Therap"},{"key":"R22-17-20210210","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/000313480907501025","article-title":"Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates?","volume":"75","author":"Cannom","year":"2009","journal-title":"Am Surg"},{"key":"R23-17-20210210","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1524-4733.2008.00335.x","article-title":"Loss of treatment response to infliximab maintenance therapy in Crohns disease: a payor perspective.","volume":"11","author":"Wu","year":"2008","journal-title":"Value Health"},{"key":"R24-17-20210210","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/rheumatology\/keh034","article-title":"Do rheumatology cost-effectiveness analyses make sense?","volume":"43","author":"Wolfe","year":"2004","journal-title":"Rheumatology"},{"key":"R25-17-20210210","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/00003495-200565040-00004","article-title":"NJ, regier DA, Ara R et al. An overview of economic evaluations for drugs used in rheumatoid arthritis.","volume":"65","year":"2005","journal-title":"Drugs"},{"key":"R26-17-20210210","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":", Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohns disease: an open randomised trial.","volume":"371","author":"DHaens","year":"2008","journal-title":"Lancet"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2010139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2010139","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2010139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201009000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:48:58Z","timestamp":1786542538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201009000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2010.139","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}